142 related articles for article (PubMed ID: 22207322)
1. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
Martin-Malo A; Merino A; Carracedo J; Alvarez-Lara MA; Ojeda R; Soriano S; Crespo R; Ramirez R; Aljama P
Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
[TBL] [Abstract][Full Text] [Related]
2. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
3. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
Guz G; Glorieux GL; De Smet R; Waterloos MA; Vanholder RC; Dhondt AW
Nephrol Dial Transplant; 2006 Oct; 21(10):2834-40. PubMed ID: 16762960
[TBL] [Abstract][Full Text] [Related]
4. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
5. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
6. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
8. Acute and subacute effects of EV iron sucrose on endothelial functions in hemodialysis patients.
Ozkurt S; Ozenc F; Degirmenci NA; Temiz G; Musmul A; Sahin G; Yalcin AU
Ren Fail; 2012; 34(1):1-6. PubMed ID: 22017464
[TBL] [Abstract][Full Text] [Related]
9. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
Rangel EB; Espósito BP; Carneiro FD; Mallet AC; Matos AC; Andreoli MC; Guimarães-Souza NK; Santos BF
Ther Apher Dial; 2010 Apr; 14(2):186-92. PubMed ID: 20438541
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
12. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
13. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
15. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron sucrose changes the intraperitoneal homeostasis.
Breborowicz A; Połubinska A; Kupczyk M; Wanic-Kossowka M; Oreopoulos DG
Blood Purif; 2009; 28(1):53-8. PubMed ID: 19325240
[TBL] [Abstract][Full Text] [Related]
17. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
18. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
19. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
20. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]